Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2019 07:00 ET | Source: Arch Biopartners

Arch Provides Interim Update on Phase I Trial for Metablok (LSALT Peptide)

TORONTO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Phase I human trial of Metablok (LSALT...
August 22, 2019 12:24 ET | Source: Arch Biopartners

Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate Metablok in the Prevention of Inflammation and Organ Damage

TORONTO, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that a scientific team led by Dr. Donna Senger, Dr....
June 19, 2019 07:20 ET | Source: Arch Biopartners

Arch Biopartners Announces Start of Phase I Human Trial for Metablok

TORONTO, June 19, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has initiated the Phase I human trial for...
May 22, 2019 17:01 ET | Source: Arch Biopartners

Arch Biopartners Closes Convertible Note Financing

TORONTO, May 22, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has closed the non-brokered, unsecured convertible note...
May 17, 2019 07:00 ET | Source: Arch Biopartners

Arch Biopartners Arranges Convertible Note Financing

TORONTO, May 17, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has arranged a non-brokered, unsecured convertible note...
March 19, 2019 10:06 ET | Source: Arch Biopartners

UPDATE - Arch Biopartners Receives Approval to Perform Phase I Clinical Trial for Metablok in Australia

TORONTO, March 19, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), today announced that it has been granted approval by the Alfred...
March 19, 2019 08:46 ET | Source: Arch Biopartners

Arch Biopartners Receives Approval to Perform Phase I Clincial Trial for Metablok in Australia

TORONTO, March 19, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), today announced that it has been granted approval by the Alfred...
February 07, 2019 08:00 ET | Source: Arch Biopartners

Arch Biopartners Awarded NRC-IRAP Funding to Further Develop Metablok Drug Program

TORONTO, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), today announced that the National Research Council – Industrial...
January 29, 2019 08:46 ET | Source: Arch Biopartners

Arch Biopartners Closes Convertible Note Financing

TORONTO, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has closed the non-brokered, unsecured convertible note...
January 24, 2019 08:43 ET | Source: Arch Biopartners

Arch Biopartners Arranges Convertible Note Financing

TORONTO, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has arranged a non-brokered, unsecured convertible note...

Next Page keyboard_arrow_right